Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
Bottneuro is pleased to announce that its MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
Over the next three years, the project “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer’s disease” will validate a personalised, home-based, non-invasive neuromodulation therapy designed to address one of the most pressing challenges in healthcare.
Addressing a Critical Gap in Alzheimer’s Care
Alzheimer’s disease remains a major global health burden, with limited effective and scalable treatment options - particularly in early stages. This project brings together clinical research, personalised neuromodulation, biomarker development, and health-economic evaluation to create a viable and accessible therapeutic solution.
Clinical Validation of MIAMIND®
At the core of the study is a personalised, multi-step tDCS/tACS protocol delivered via the MIAMIND® neurostimulator. MIAMIND® is currently the only system enabling MRI-guided, multifocal transcranial electrical stimulation (tES) designed for safe self-administration at home.
The trial will investigate:
- Symptomatic effects: Improvement in episodic memory after 4 weeks of at-home therapy
- Disease-modifying potential: Sustained cognitive and biological changes, including cerebral blood flow and connectivity
- Monitoring biomarkers: Tools to optimise treatment delivery and reduce clinical burden
- Predictive biomarkers: Identification of responders to enable personalised and cost-effective care
- Health Technology Assessment: Evaluation of cost-effectiveness to support future reimbursement pathways
From Clinical Evidence to Real-World Impact
As MIAMIND® is already available in Switzerland as a custom-made medical device, successful study outcomes can be rapidly translated into clinical practice. This creates a unique opportunity to accelerate adoption and deliver value to patients and healthcare systems even ahead of larger regulatory trials.
Strong Academic–Industry Collaboration
The project is led in collaboration with Jessica Peter at the University of Bern, bringing expertise in Alzheimer’s disease, neuromodulation, and advanced neuroimaging. Bottneuro contributes its proprietary MIAMIND® technology, regulatory capabilities, and commercial pathway to ensure effective translation into clinical use.
